18th May 2015 14:36
Verona Pharma plc
("Verona Pharma" or the "Company")
Director Dealings
18 May 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received notification that on 15 and 18 May 2015 Directors of the Company purchased ordinary shares of 0.1 pence each of the Company ("Ordinary Shares"). The details of the trades are shown in the table below.
Director | Ordinary Shares Purchased | Date | Average Price (p) | Total interest in the Company | As a % of the total share capital |
Dr. David Ebsworth | 300,000 | 18/05/2015 | 3.50 | 3,579,774 | 0.35% |
Dr. Jan-Anders Karlsson | 135,000 | 15/05/2015 | 3.40 | 2,870,000 | 0.28% |
Biresh Roy | 150,000 | 18/05/2015 | 3.50 | 900,000 | 0.09% |
-Ends-
For further information please contact:
Verona Pharma plc | Tel: +44 (0) 20 3283 4200 |
Jan-Anders Karlsson, CEO |
|
|
|
N+1 Singer | Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting | Tel: +44 (0)20 3727 1000 |
Julia Phillips / Simon Conway |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.
Related Shares:
VRP.L